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Abstract 
Background: Despite an increased propensity to primary failure in forearm 
arteriovenous fistulae compared to upper arm fistulae, forearm fistulae remain the 
preferred primary access type for chronic hemodialysis patients.  In a high risk patient 
population with multiple medical comorbidities associated with requirement for 
intravenous access we compared the rates of access failure in forearm and upper arm 
fistulae.  Materials and Methods: The records of all patients having primary native 
arteriovenous fistulae placed between 2004 and 2009 at the VA Connecticut Healthcare 
system were reviewed (n=118). Primary and secondary patency of upper arm and forearm 
fistulae were evaluated using Kaplan-Meier survival analysis. The effects of medical 
comorbidities on access patency were analyzed with Cox regression.  Results: The 
median time to primary failure of the vascular access was 0.288 years in the forearm 
group compared to 0.940 years in the upper arm group (p=0.028).   Secondary patency 
was 52% at 4.9 years in upper arm fistulae compared to 52% at 1.1 years in the forearm 
group (p=0.036).  There was no significant effect of patient comorbidities on fistula 
failure; however, there was a trend toward upper arm surgical site as a protective factor 
for primary fistula patency (Hazard Ratio=0.573, p=0.076).  Conclusions: In veterans 
needing hemodialysis, a high risk population with extensive comorbid factors often 
requiring intravascular  access, upper arm fistulae are not only a viable option for primary 
vascular access, but are likely to be a superior option to classic forearm fistulae. 
 
Keywords: Arteriovenous fistula, radiocephalic fistula, brachiocephalic fistula, 
hemodialysis, vascular patency, veteran, risk factor. 
 
 
 
 
Table of Contents 
Introduction          page 
End-stage Renal Disease: Increasing Incidence and Prevalence                    5 
Anatomy of Hemodialysis Access      7 
History of Hemodialysis Vascular Access                                                      9 
Modern Vascular Access Patency                                                                   13 
Materials and Methods         16 
Results           19 
AV Fistula  
Patient Demographics and Comorbidities     19 
Preoperative Labs, Measures and Medications    20 
Surgical and Postoperative Variables      20 
Access Patency        21 
Patient Survival        22 
Discussion           31 
References           37 
Appendix           43 
5 
 
 
 
End-Stage Renal Disease: Increasing Incidence and Prevalence 
 The incidence and prevalence of chronic kidney disease (CKD) has increased 
consistently both worldwide and in the United States over the past decades.   Since 1973, 
enrollment in the Medicare funded end-stage renal disease (ESRD) program has 
increased dramatically.  In 1973, 10,000 patients were enrolled in the ESRD program. 
By1983, enrollment had reached 86, 354 patients, and has continued to expand, having 
reached a total of 527, 283 patients as of December 31, 2007 (1, 2).  There were an 
estimated 111,000 incident cases recorded in that same year. In 2010, the projected 
number of ESRD patients was estimated to be 651,330, which amounts to a total cost of 
over $28 billion US healthcare dollars(3). These numbers underscore the importance of 
developing effective and reliable care for this rapidly growing population.  
The rising prevalence of CKD is mainly attributable to an increase in the number 
of patients who undergo renal replacement therapy each year, and to a lesser degree, the 
somewhat increased survival of ESRD patients (1, 2).  But in spite of the resources 
committed to the ESRD population and improvements in modern dialysis techniques, the 
population continues to experience substantial morbidity and mortality. ESRD patients 
are well known to have poor long-term survival in comparison to the population as a 
whole.  In 2007 alone, over 87,800 ESRD patients died (1, 2).  Furthermore, dialysis 
patients have been shown to have a reduced quality of life relative to the general 
population. As such, the impact of the quality of care these patients receive cannot be 
overstated (3-5). 
Maintaining permanent intravenous access in ESRD patients has proven to be a 
difficult task, especially as the number of patients with comorbid conditions continues to 
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grow.  Approximately 50% of ESRD patients have three or more comorbid medical 
conditions, and each patient is hospitalized on average 12.6 days per year (1, 2).  In fact, 
vascular access complications and failures are not only a major cause of morbidity and 
mortality in ESRD patients, but were the most frequent reason for patient hospitalization 
cited by the National Kidney Foundation in 1997 (1, 6).  In total, vascular access 
accounts for 14% of all ESRD costs, a total of $1 billion United States healthcare dollars 
yearly (1).   
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Anatomy of Hemodialysis Access  
A major challenge in accommodating the growing ESRD population has been the 
creation of permanent, reliable vascular access for hemodialysis (HD) delivery.  In order 
to establish durable arteriovenous (AV) access for chronic HD, access blood flow and 
blood pressure must be sufficient to support modern dialysis flow pumps. Such pumps 
target access blood flow rates of 300-450 ml/min, and diasylate flow rates of 500-800 
ml/min. To meet and maintain these pressure requirements, successful AV access must 
include a feeding artery that can transfer high pressures to a compliant, distensible venous 
outflow.  Additional sources of resistance to blood flow, such as venous or arterial 
stenosis, partial or complete thrombosis, and accessory vein outflow can thus 
compromise the dialysis process.  For this reason, an understanding of the vascular 
anatomy of the upper extremity is essential to creating permanent intravascular access.    
In choosing a vein for chronic access creation, a nonsclerotic segment of either a 
deep or superficial vein that is at least 3 millimeters in diameter is identified, either via 
physical exam or preoperative venous mapping, to be anastomosed to an artery(7). 
Selecting an appropriately sized vein is important, as larger veins have been associated 
with successful fistula maturation. Specifically, the use of veins with diameters greater 
then 4 mm have been associated with the creation of a functional AV fistula that is able 
accommodate the high flow rates of dialysis pumps (8).  This relationship can be 
understood logically in terms of Pouseuille’s law, which states that blood flow is 
proportional to the product of the change in pressure gradient and the fourth power of the 
vessel radius, divided by the viscosity of blood. Though not able to entirely account for 
the properties of arteries and pulsatile blood flow, Pouseuille’s law can in some ways 
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explain the hemodynamics of AV fistulae, specifically why vein diameter, as a major 
predictor of vessel resistance, has an effect on fistula maturation.   
In general, upper arm veins are larger then the venous branches in the forearm (9).  
In the upper arm, the deep venous system includes the brachial and basilic veins that run 
parallel to the brachial artery.  The basilic vein is the most commonly used deep vein in 
HD access creation.   When creating a transposed basilic vein fistula, the basilic vein is 
first mobilized at the medial aspect of the upper arm, and then transposed superficially 
through the deep fascia and anastomosed to the brachial artery. Both the brachial and 
basilic veins join to form the axillary vein in the upper arm, and later, the subclavian vein 
from the first rib to the end of the clavicle . The deep brachial vein is rarely used for 
access (10). 
For initial HD access creation, however, the superficial venous system, especially 
the forearm cephalic vein, is most commonly used. The cephalic vein in the forearm can 
be used in conjunction with the radial artery to create a radiocephalic fistula at the wrist 
or snuffbox, while the upper arm segment of the cephalic vein at the elbow can be used 
for brachiocephalic access with the brachial artery.  The distal basilic vein, which courses 
superficially in the forearm on the ulnar side of the wrist, and the median basilic vein at 
the elbow, are less commonly used for forearm AV fistula creation.   The radial and ulnar 
veins, which are not generally used for HD access, compose the deep veins of the 
forearm (10).  
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History of Hemodialysis Vascular Access 
 The first hemodialysis treatment in a human was performed by Georg Haas, of 
Germany, in 1924 and lasted only 15 minutes.  Haas used a glass cannula to withdraw 
arterial blood from the radial artery, which he then returned to the patient’s cubital vein.  
He later modified his vascular access to include a surgical cut-down that cannulated both 
the artery and an adjacent vein simultaneously.  With support from the Rockefeller 
Foundation, he performed a total of 11 HD treatments by 1929 before losing financial 
and clinical support.  By his death in 1971, he had witnessed the transformation in the 
care of ESRD that followed the development of modern dialysis techniques (11).  
In 1966, Brescia et al. published a landmark paper that first described the AV 
fistula as a type of permanent access for HD patients.  A total of 15 surgical fistulae were 
described in this paper, the first of which was created in February of 1965.  In this paper, 
the group’s surgeon, Dr. Appell, described performing a side-to-side anastomosis 
between the radial artery and the cephalic antebrachial vein at the wrist.  He did so by 
making a 3-5 mm incision over the lateral surfaces of the artery and vein, which were 
then sutured with arterial silk continuously.  Remarkably, of the 14 fistulae included in 
this study, Brescia and his colleagues reported only 2 primary failures (12).  It is worth 
mentioning that a similar technique was described by Jaboulay and Briau, of France, who 
published a method of creating an experimental artery-end-to end anastomosis in dogs in 
1896 (13).  Several years later, Alexis Carrel, also of France, described a three point end-
to-end, as well as a side-to-side anastomosis as a means of creating vascular access (14).  
Carrel went on to receive the Nobel Prize in 1912 for this development (11).   
10 
 
 
 
 Following Brescia and Cimino’s advances, two more methods of creating surgical 
fistulae were developed.  The first of these methods, an end-to-end anastomosis between 
the radial artery and cephalic vein at the wrist, has been largely abandoned due to high 
rates of steal syndrome and early failure in the growing elderly and diabetic dialysis 
population (15).  Though not typically used for initial access placement procedures 
currently, this method is still relied upon in AV fistula revision procedures.  A second 
and more successful method of creating a radiocephalic fistula was described by Lars 
Rohl in 1968.  Rohl’s paper detailed the creation of radial-artery-side-to-vein-end-
anastomoses in 30 HD patients.  The procedure he described involved ligating the radial 
artery distal to the AV anastomosis, essentially creating a modified end-to-end 
anastomosis.  This technique had the advantage of making laterally located cephalic 
veins, which had previously been unusable for side-to-side anastomoses, suitable for 
access creation (16).  Later, the distal artery anastomosis was discarded, except for use in 
patients experiencing post-operative ischemia of the upper extremity.  This artery-side-to-
vein-end anastomosis remains the standard surgical operation performed today (11).  
 Perhaps one of the most important modern developments in vascular access was 
the synthetic AV graft.  Still the most frequently used synthetic graft material,  
polytetrafluoroethylene (PTFE) was used in animals in 1972, and saw its first use in 
patients by L.D. Baker in 1976 when he published the results of using PTFE grafts as 
venous prosthesis in 72 HD patients (17, 18).  This method was extremely useful in 
patients for whom native AV fistulae could not be created (18-21).  In the 1980s, central 
venous catheters (CVC) also gained popularity as a means of prolonging temporary HD 
access (22-24).  Overall, these developments led to a reduction in AV fistulae use and an 
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increase in both CVC and synthetic grafts for chronic HD.  This, in turn, led to increased 
cost of ESRD patient care, with upwards of 73% of patients initiating dialysis requiring 
hospitalization in the early 1990s (6, 25) 
 The National Kidney Foundation first published the Kidney Disease Outcomes 
Quality Initiative (K/DOQI) Clinical Practice Guidelines for Vascular Access in 1997 in 
an effort to improve vascular access outcomes through both evidence and opinion based 
standards of care (1).  Shortly after this, Medicare published clinical performance 
measures based on K/DOQI, in order to reduce costs and improve patient care.  These 
measures included the proportion of HD patients with AV fistulae access, the proportion 
of patients with central catheter access, and required frequent monitoring of AV grafts for 
stenosis (25).  Nonetheless, in 2002 the total cost of the ESRD Medicare program had 
further increased to $17 billion dollars and the number of procedures required to maintain 
vascular access was four times greater than those needed in 1991 (26).  
 In 2003, the Centers for Medicare and Medicaid Services and the ESRD network 
began the Fistula First Initiative (FFI) in an effort to increase AV fistulae usage and 
decrease the use of CVC for chronic dialysis.  Specifically, FFI aimed to achieve 
K/DOQI guidelines of 50% AV fistula usage in incident, and 40% in prevalent patients.  
In 2006, this goal was modified to include 65% of prevalent patients in 2006 (25).  
Though FFI has certainly increased fistula use, it has had several unexpected results, 
which included the failure of FFI to decrease catheter use to less than 10% of prevalent 
HD patients; trends following FFI were quite the opposite.  
 Since FFI began, there has been a progressive increase in CVC use by ESRD 
patients.  The majority of patients in North America continue to start HD with a CVC, in 
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spite of adequate AV fistula planning and placement (27-29).  In 2006, of those patients 
initiating HD, 82% used a CVC for vascular access.  Since indwelling dialysis catheters 
are associated with increased patient mortality as well as an increased risk of sepsis (30-
34), these outcomes highlight the need for a shift in current practice paradigms. This 
would include a shift towards not only increased AV fistula placement, but of improved 
functionality and durability of those fistulae that are placed. 
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Modern Vascular Access Patency 
Creating and maintaining long-term access for HD remains both a clinical 
challenge and necessity.  In the approach to modern HD access, three principal types of 
vascular access are used.  Among these are autogenous AV fistulae, synthetic AV grafts, 
and tunneled, cuffed central venous catheters.  Arteriovenous (AV) fistulae are the 
preferred access type for chronic hemodialysis patients, with current practice guidelines 
choosing radiocephalic forearm fistulae as the preferred initial location for primary 
vascular access, followed by brachiocephalic and brachiobasilic upper arm fistulae, 
respectively (35, 36).  When placed prior to the initiation of hemodialysis fistulae are 
preferred as they eliminate the need for indwelling dialysis catheters, which are 
associated with increased patient mortality as well as an increased risk of sepsis (30-34).  
Prosthetic AV grafts, while also preferred to central venous catheters, are generally 
reserved for use in patients with inadequate native vasculature as they have worse long-
term patency and increased rates of infection compared to native fistulae (37).  
Nonetheless, AV fistulae are not without their own complications, including thrombosis, 
infection, aneurysm, seromas, steal syndrome, heart failure, and bleeding, complicating 
the placement algorithm. 
When monitoring fistula functionality, primary fistula patency is defined as the 
amount of time that a surgical fistula can reliably support dialysis without requiring 
additional procedures or interventions to maintain or improve fistula patency. If 
additional procedures are required to support a particular AV access site, a period of 
secondary fistula patency begins. These interventions can include angioplasty, 
thrombectomy, various interventional radiology procedures, accessory vein ligations, and 
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redo surgeries. If such procedures are successful in salvaging a fitsula, a period of 
cumulative secondary patency can be calculated, which includes the entire duration of 
fistula functionality from initial surgical creation until ultimate access failure.  Access 
failure is defined as site abandonment necessitating new AV access creation at another 
anatomical site.  For those patients already reliant upon HD, this requires a period of 
reliance upon CVC while new access is placed.  
 In a systematic review of 34 modern access patency studies, primary patency 
rates of upper arm fistulae were approximately 81% and 60%, at 6 and 18 months, 
respectively, compared to 71% and 49%, in forearm fistulae at 6 and 18 months.   
Likewise, primary patency rates of upper arm prosthetic grafts were approximately 69% 
and 49%, at 6 and 18 months, respectively, compared to 51% and 28%, in forearm grafts 
at 6 and 18 months (37).  As such, many patients with AV access require invasive 
procedures to maintain secondary patency; otherwise the site may need to be abandoned 
and a new access performed.  
Although access failure rates have varied slightly from study to study and across 
patient populations, forearm fistulae in particular are well documented as failing to 
mature at rates greater than that of upper arm fistulae (37, 38).  In spite of this, forearm 
fistulae remain the primary vascular access of choice due to relative ease of creation and 
preservation of proximal vasculature for future access attempts.  Although K/DOQI 
endorses this distal to proximal approach to access creation, there are no randomized 
control studies to date that have evaluated this classic algorithm.   
We evaluated primary and secondary patency rates of upper arm and forearm AV 
access when placed for primary hemodialysis access in veterans.  We have previously 
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shown that veterans often have large numbers of comorbid medical conditions compared 
to nonveterans, suggesting that this population is at particularly high risk for 
complications (39, 40).  We hypothesized that, since patients with multiple medical 
comorbidities often require high rates of intravascular (IV) access, high risk patients may 
have particularly poor rates of forearm access maturation.  If veterans have poor rates of 
access maturation, then upper arm fistulae may be preferred in these patients. 
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Materials and Methods 
 
The records of all patients who underwent primary AV access creation at the VA 
Connecticut Healthcare System (West Haven, CT) between April 2004 and December 
2009 were reviewed.  Patients were identified using the VA Department of Surgery’s 
case list of all vascular procedures performed between April 2004 and December 2009.  
Once all access creations were identified, follow up data through June 2010 was retrieved 
from the VA Computerized Patient Record System.  IRB approval was obtained from the 
West Haven VA.  Patients were excluded from the study if they had a previous AV 
fistula or graft placed prior to April 2004.  Patients who did not receive autogenous AV 
fistulae were also excluded for the study.   In patients who had two or more access 
placements during the study period, only data pertaining to the initial operation was 
collected. Selection for forearm or upper arm fistulae was at the operative surgeon’s 
discretion and included factors such as presence of a palpable vein as well as the venous 
diameter recorded on preoperative duplex mapping. 
Patient demographics were determined via chart review, and included age, race, 
and gender.  Patient charts were evaluated for the preoperative presence or absence of the 
following comorbidities: hypertension, diabetes mellitus, current smoking, current 
dialysis, congestive heart failure (CHF), coronary artery disease (CAD), pulmonary 
disease, stroke, transient ischemic attack (TIA), and cancer.  Preoperative laboratory 
values included albumin and creatinine.  Preoperative measures evaluated were body 
mass index (BMI) and ejection fraction (EF, %).  Patient medications were reviewed for 
the presence or absence of prescribed aspirin (ASA), anti-platelet agents, anticoagulation 
agents, and statin therapy.  Surgical variables included: surgical site (upper arm, i.e. 
17 
 
 
 
brachiocephalic or basilic access; forearm, i.e. radiocephalic access), surgical side (right 
or left), and size of upper arm and forearm veins as recorded on preoperative duplex 
(cephalic at the distal humerus and cephalic at the wrist, respectively).  Postoperative 
variables recorded included known use of the access for successful hemodialysis.   Study 
data was maintained in a de-identified database. 
The primary study outcomes were fistula status (patent versus failed) and duration 
of fistula patency. Primary patency was calculated as the time period between the date of 
access placement and the date of either the last follow-up with known fistula patency 
without failure, or until the date of first fistula failure.  Secondary patency was calculated 
as the time period between the date of access placement and the date of either the last 
follow-up with known fistula patency without failure, or until the date of absolute fistula 
failure requiring disuse and site abandonment, i.e. including all secondary procedures to 
maintain the access.  Patients who switched to peritoneal dialysis, received renal 
transplants, or no longer required HD due to renal recovery were considered to have 
patent fistulae until the date of dialysis completion.   Postoperative survival outcomes 
included date of death or date of last follow-up in the VA records and patient status 
(deceased or living).  Length of survival was calculated using the date of fistula access as 
the baseline. 
Data analysis was performed on both the entire study population (including all 
access types) and on only those patients who underwent native AV fistulae creations, 
excluding patients who receive synthetic AV grafts.  Results are reported as mean ± 
SEM.  Statistical analysis was performed with SigmaPlot 11.0 (Systat Software, San Jose, 
CA).  The study population was divided by upper or forearm fistula site and analyzed 
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across these two groups. Categorical variables were analyzed using Chi-square test, and 
continuous variables were analyzed using the t-test.  Primary and secondary patencies 
were analyzed using Kaplan-Meier statistics, and the difference between the upper and 
forearm strata were compared using the Gehan-Breslow statistic.  Overall survival of the 
study population was analyzed using Kaplan-Meier statistics.  The effect of all 
independent patient demographic variables collected on primary fistula patency and long-
term survival of the study population was analyzed with Cox regression. 
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Results 
Patient Demographics and Comorbidities 
A total of 118 patients underwent primary AV fistula placement at the VA 
Connecticut Healthcare System between April 2004 and December 2009.  Of these 
patients, 44 had upper arm fistulae and 74 had forearm fistulae.  There were 11 patients in 
the upper arm group that underwent basilic transpositions for primary access.  The 
remaining 33 patients received brachiocephalic access.  In the forearm strata, 43 patients 
had radiocephalic access placed.  One patient had a radial-interosseus vein fistula placed.   
The demographics of the study population are listed in Table 1.  There were 116 
men and 2 women. The mean age of patients who had upper arm fistulae was 65.8 ± 1.9 
years, and the mean age of patients who had forearm fistulae was 65.8 ± 1.4 years; there 
was no significant difference between these two groups (p= 0.985).  All of the patients 
were either Caucasian (67.8%) or African American (32.2%); patient race did not vary 
across groups (p= 0.785). 
Hypertension was highly prevalent in patients with either upper (97.7%) or 
forearm fistulae (100%).  Diabetes mellitus had a similar prevalence across the two 
groups, present in 39.8% of the upper arm patients and 35.1% of the forearm patients 
(p=0.247).  30.5% of patients reported current tobacco use at the time of fistula 
placement; current tobacco use was more prevalent in the forearm group than the upper 
arm group (40.5% versus 13.6%; p=0.004).  Patients who were receiving dialysis at the 
time of their operation were evenly distributed across the groups (40.9% upper arm vs. 
44.6% forearm; p=0.929).  50% of patients were identified as having heart disease; there 
was no difference in prevalence across the upper and forearm groups (p=0.792); both 
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CAD (p=0.997) and CHF (p=0.139) were similarly distributed across the study groups.   
There was no significant difference between the two groups in prevalence of pulmonary 
disease (p=0.186).  Prior stroke and TIA were identified in 11.4% and 0% of the upper 
arm patients and 14.9% and 2.7% of the forearm patients, respectively; however this was 
not statistically significant (stroke, p=0.795; TIA, p=0.717).  17% of patients had a 
diagnosis of cancer at the time of operation, which was similar between groups (p=.300).   
 
 
Preoperative Labs, Measures, and Medications 
The mean preoperative albumin in the study population was 3.1 ± 0.1 g/dL and 
did not vary across groups (p=0.157).  The mean creatinine was 5.2 ± 0.2 mg/dL; 
preoperative creatinine also did not vary between the surgical site groups (p=0.304).  
BMI and EF were similar across the upper and forearm groups (p=0.799 and p=0.903, 
respectively)  
At the preoperative visit 39.8% of patients were taking aspirin, 4.24% were taking 
an antiplatelet agent, 19.5% of patients were anticoagulated, and 59.3% of patients were 
taking a statin; these medications did not vary significantly across groups (p=.535-.971).  
 
Surgical and Postoperative Variables 
The majority of study patients received left upper extremity fistulae (84.8%, 
n=100); however the distribution of surgical side did not vary significantly between 
groups (p=0.344).   Preoperative duplex ultrasound vein mapping showed a significant 
difference between cephalic vein size at the wrist in the upper and forearm groups; 
patients who received forearm fistulae had a mean cephalic vein width at the wrist of 0.15 
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± .021 cm compared to a width of 0.08 ± .021 cm in patients who had an upper arm 
fistula placed (p=.016).  The cephalic vein diameter at the distal humerus was similar 
between the two groups, measuring 0.320 ± .0317 cm in the upper arm group and 0.35 ± 
.024 cm in the forearm group (p=.405).  The number of patients that were successfully 
dialyzed through their primary AV fistula at least once did not vary across groups 
(p=0.666). 
 
Access Patency 
Cumulative primary patency was reduced in forearm fistulae compared to upper 
arm fistulae, with forearm fistulae having only 34% primary patency at 1 year compared 
to 41% at 1 year for upper arm fistulae; the median time to primary failure of the vascular 
access was 0.288 ± 0.164 years in the forearm group compared to 0.940  ± 0.456 years in 
the upper arm group (Figure 1A; p=0.028).  Similarly, cumulative secondary patency was 
also reduced in forearm fistulae compared to upper arm fistulae; secondary patency was 
52% at 4.9 years in upper arm fistulae compared to 52% at 1.1 years in the forearm group 
(Figure 1B; p=0.036). 
Cox regression analysis of factors affecting primary fistula patency showed no 
significant effect of patient comorbidities, laboratory values, or medications on fistula 
failure (Table 2).  There was a trend towards upper arm surgical site being a protective 
factor (hazard ratio=0.573; p=0.076); surgical side did not affect fistula patency 
(p=0.901).  
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Patient Survival 
There were 35 (29.7%) patient deaths in the study group.  Cumulative survival 
analysis reflected poor survival in this patient population, with 88% survival at 1 year, 
62% survival at 3 years, and 58% survival at 5 years after fistula placement (Figure 2).  
The only preoperative demographic factor that was associated with reduced mortality was 
use of an anti-platelet agent (Table 3; hazard ratio=4.3; p=0.019).  The surgical site, 
upper arm versus forearm, did not influence patient mortality (hazard ratio=0.956; 
p=0.919).   
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Table 1.  Demographics and risk factors of AV Fistulae Patients 
Variable Total  (n)  
Total 
(%) 
Upper 
Arm Upper (%) Forearm  Forearm (%) p-value 
Total Patients 
(n) 
118  44 37.3% 74 62.7%  
Age (yrs) 65.8±1.1  65.8 ± 1.8  65.8±  1.4  0.985 
Race        
Caucasian 80 67.8% 31 75.0% 49 66.2% 0.785 
African 
American 
38 32.2% 13 29.5% 25 33.8%  
Gender        
Male 116 98.3% 43 97.7% 73 98.6% 0.717 
Female 2 1.7% 1 2.3% 1 1.4%  
Comorbidities        
Hypertension        
Yes 117 99.2% 43 97.7% 74 100.0% 0.792 
No 1 0.8% 1 2.3% 0 0.0%  
Diabetes 
Mellitus 
       
Yes 47 39.8% 21 47.7% 26 35.1% 0.247 
No 71 60.2% 23 52.3% 48 64.9%  
Current 
Smoker 
       
Yes 36 30.5% 6 13.6% 30 40.5% 0.004 
No 82 69.5% 38 86.4% 44 59.5%  
Current 
Dialysis 
       
Yes 51 43.2% 18 40.9% 33 44.6% 0.843 
No 67 56.8% 26 59.1% 41 55.4%  
Heart Disease 
(CAD or CHF) 
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Yes 59 50.0% 21 47.7% 38 51.4% 0.792 
No 59 50.0% 23 52.3% 36 48.6%  
CAD        
Yes 55 46.6% 21 47.7% 34 45.9% 0.997 
No 63 53.4% 23 52.3% 40 54.1%  
CHF        
Yes 23 19.5% 5 11.4% 18 24.3% 0.139 
No 95 80.5% 39 88.6% 56 75.7%  
Pulmonary 
Disease 
       
Yes 31 26.3% 8 18.2% 23 31.1% 0.186 
No 87 73.7% 36 81.8% 51 68.9%  
Stroke        
Yes 16 13.6% 5 11.4% 11 14.9% 0.795 
No 102 86.4% 39 88.6% 63 85.1%  
TIA        
Yes 2 1.7% 0 0.0% 2 2.7% 0.717 
No 120 98.4% 44 100.0% 72 97.3%  
Cancer        
Yes 20 16.9% 10 22.7% 10 13.5% 0.3 
No 98 83.1% 34 77.3% 64 86.5%  
Preoperative 
Labs 
       
Albumin 
(g/dL) 
3.1± .1  2.9± .2  3.2± .1  0.157 
Creatinine 
(mg/dL) 
5.2± .2  4.9± .3  5.3± .3  0.304 
Preoperative 
Measures 
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BMI 28.4± .8  28.2± 1.4  28.2± 1.4  0.799 
LVEF (%) 42.7± 2.4  42.3± 4.0  43.0± 3.1  0.903 
Medications        
ASA        
Yes 47 39.8% 16 36.4% 31 41.9% 0.69 
No 71 60.2% 28 63.6% 43 58.1%  
Anti-platelet        
Yes 5 4.2% 1 2.3% 4 5.4% 0.731 
No 113 95.8% 43 97.7% 70 94.6%  
Anticoagulated        
Yes 24 19.7% 9 19.6% 15 19.7% 0.832 
No 98 80.3% 37 80.4% 61 80.3%  
Statin        
Yes 70 59.3% 24 54.5% 46 62.2% 0.535 
No 48 40.7% 20 45.5% 28 37.8%  
Surgical 
Variables 
       
Side        
Right 18 18.0% 9 20.5% 9 12.2% 0.344 
Left 100 84.7% 35 79.5% 65 87.8%  
Duplex U/S 
Vein Mapping 
 
       
Cephalic @ 
Wrist (cm) 
 
.13± .02  .08± .02  .15± .02  0.016 
Cephalic 
@Distal 
Humerus (cm) 
.34± .02  .32± .03  .35± .02  0.405 
Postoperative 
Variables 
       
AVF Used?        
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Yes 50 42.4% 20 45.5% 30 40.5% 0.666 
No 63 53.4% 23 52.3% 40 54.1%  
Unknown 5 4.2% 1 2.3% 4 9.1%  
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Table 2.  Cox Proportional Hazards Analysis of Factors affecting Primary Fistula Patency. 
Covariate 
Hazard  
Ratio 95%Conf-L 95%Conf-U p-value 
Age 1.0 1.0 1.0 0.718 
Comorbidities      
Hypertension 1.3 0.1 13.1 0.798 
Diabetes Mellitus 1.1 0.6 2.0 0.739 
Current Smoking 0.9 0.5 1.6 0.669 
Current Dialysis 1.1 0.6 2.1 0.718 
Heart disease (CHF or 
CAD) 
1.0 0.5 1.8 0.899 
Pulmonary Disease 0.9 0.5 1.6 0.656 
Cancer 1.1 0.5 2.2 0.859 
Preoperative Labs      
Albumin 0.9 0.7 1.1 0.35 
Creatinine 1.0 0.8 1.1 0.528 
Preoperative Measures      
BMI 1.0 1.0 1.0 0.949 
LVEF (%) 1.0 1.0 1.0 0.606 
Medications      
ASA 0.9 0.5 1.6 0.775 
Antiplatelet 0.5 0.1 2.4 0.419 
Anticoagulated 1.0 0.5 2.0 0.941 
Statin 1.2 0.6 2.1 0.631 
Surgical Variables      
Site-Upper arm 0.6 0.3 1.1 0.076 
Side 1.0 0.5 2.0 0.901 
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Table 3. Cox Proportional Hazards Analysis of Factors Affecting Patient Survival. 
Covariate 
Hazard 
Ratio 95%Conf-L 95%Conf-U p-value 
Age 1.027 0.986 1.069 0.201 
Comorbidities         
Hypertension 9.34E-08 0                ∞ 0.998 
Diabetes Mellitus 1.881 0.815 4.34 0.139 
Current Smoking 0.943 0.39 2.28 0.897 
Current Dialysis 1.411 0.559 3.559 0.466 
Heart disease (CHF or 
CAD) 
0.649 0.253 1.665 0.368 
Pulmonary Disease 1.264 0.505 3.165 0.617 
Cancer 1.001 0.351 2.86 0.998 
Preoperative Labs         
Albumin 0.864 0.609 1.227 0.415 
Creatinine 1.032 0.863 1.234 0.732 
Preoperative Measures 
        
BMI 1 0.952 1.051 0.996 
LVEF (%) 1.007 0.992 1.022 0.394 
Medications         
ASA 0.711 0.303 1.671 0.434 
Antiplatelet 4.314 1.273 14.62 0.019 
Anticoagulated 0.78 0.309 1.97 0.599 
Statin 1.068 0.45 2.535 0.882 
Surgical Variables         
Site-Upper arm 0.956 0.401 2.279 0.919 
Side 0.675 0.229 1.987 0.475 
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Figure 1. Primary and secondary patency of forearm vs. upper arm fistulae. (A) Kaplan-
Meier analysis of primary fistulae patency.  (B) Kaplan-Meier analysis of secondary 
fistulae patency. 
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Figure 2.  Kaplan-Meier analysis of post-operative survival  
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Discussion 
Forearm fistulae have long been the gold standard for primary hemodialysis 
access.  Our results, however, argue that forearm fistulae are far from a simple solution 
for hemodialysis access in veterans with end stage renal disease (ESRD).  In a patient 
population with reduced life expectancy, we found superior primary and secondary 
patency of upper arm access in comparison to forearm access.  We conclude that upper 
arm AV fistula are not only a viable option for primary vascular access, but are likely to 
be a superior option to classic forearm fistulae in these high-risk patients.  
           Historically, the radiocephalic fistula, which has been used for hemodialysis 
access since the mid 1960s, has been the preferred initial access site, as the wrist is easily 
accessible for the surgeon and use of this site preserves more proximal access sites for 
future placement once the wrist site fails.  Although this mode of access is appropriate for 
many patients, it is important to recognize the varying needs of the growing ESRD 
population. In 1966, when Brescia and Cimino (12) first introduced the radiocephalic 
fistula, their patients’ demographics were remarkably different than the majority of those 
patients needing dialysis today.  In their study, the average patient age was 43 years, and 
almost all of the patients required HD as a result of chronic glomerulonephritis.  At that 
time, successful HD required blood flows of 250-300 ml/min, as compared 350-450 
ml/min in modern dialysis blood pumps.  
           As hemodialysis became more prevalent in patients with diabetes in the 1970s, it 
was noticed that diabetic patients had increased rates of failure of radiocephalic fistulae 
due to both early thrombosis and low AVF blood flow (41).  These observations led to 
the suggestion that upper arm fistulae be considered for initial access in complicated 
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access patients, especially those with diabetes, hypertension, stroke, peripheral vascular 
disease, and prior amputation (41).  It was also suggested that preoperative evaluations of 
such patients include blood pressure in both arms, a meticulous search for a suitable vein, 
thorough evaluation of arterial pulses, phlebography in obese patients, x-rays to detect 
arterial calcifications, and ultrasound evaluation of both arterial and venous blood flow in 
the upper extremity (41).   
In a prospective study of 204 access patients, Dixon et al. found that primary and 
cumulative patency of upper arm native access were significantly longer than that of 
forearm access (42). In their study 1-, 3-, and 5-year cumulative secondary patency of 
upper arm AVF were 69%, 53%, and 53%, respectively, compared to 52%, 43%, and 
34% for lower arm access.  Primary patency of upper arm access was also superior to that 
of forearm access. In a larger, systematic review of 34 studies, Huber et. al. also reported 
significantly greater primary patency of upper arm native access compared to forearm 
access (60% vs. 49% at 18 mo.) (37). As such, our results are consistent with a number of 
studies in the literature that suggest that forearm fistulae are not the best option in many 
patients. 
Interestingly, we found no significant effect of patient comorbidities on access 
failure.  Access patency relies upon the presence of vasculature that can support high 
flow rates. Several patient risk factors have been previously identified as significant 
predictors of access patency, likely as a result of microvascular and macrovascular 
changes related to various comorbid conditions.  These risk factors include diabetes, age 
greater than 65 years, white race, peripheral vascular disease, and coronary artery disease 
(43). Huijbregts et al. reported peripheral vascular disease and diabetes to be significant 
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predictors of fistula failure (44).  Although our study did not identify these factors as 
predictive of access patency, our study was limited by a relatively small sample size, high 
prevalence of comorbid conditions, and homogeneity of the veteran population in this 
single center study.    Nevertheless, we were able to identify a trend towards the upper 
arm surgical site being a protective factor for primary fistula patency (Table 2), which 
agrees with the results of our cumulative patency analysis (Figure 1).  
Overall survival in the ESRD population is poor, with 5-year survival estimated to 
be 30-50% in nondiabetics, and 25% in diabetics (45).  Our results were consistent with 
these reports, with 58% survival at 5 years in our study population (Figure 2).   In 
addition, we found preoperative use of anti-platelet agents, as a proxy of underlying 
disease, to be associated with patient mortality. Mortality is typically higher in 
hemodialysis patients requiring central venous catheters and AV grafts for access 
compared to mortality patients using native access.  Using data from the U.S. Renal Data 
System Dialysis Morbidity and Mortality Study Wave 1, the relative risk of death patients 
with diabetes was shown to be greater than that of patients with native fistulae (AVG, 
relative risk=1.41, p<0.003; CVC, relative risk=1.54, p<0.002).  Similarly, in non-
diabetic patients, CVC remained associated with greater risk of mortality (relative 
risk=1.70, p<0.001), with the vast majority of complications due to infection in both 
diabetic and non-diabetic patients.  In addition, in spite of the historical association of AV 
fistulae with shunting and cardiac failure, the risk of cardiac death was greater in patients 
using CVC (diabetic relative risk=1.47, p<0.05; non-diabetic relative risk= 1.34, 
p<0.005) (30, 46).  In one report, non-fistula access was the most important risk factor for 
infection (p=0.02), with the majority of infections occurring in patients with temporary 
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vascular access such as CVC (38, 47).  As such, our findings of poor survival in these 
patients with fistulae may underestimate mortality in comparison to other ESRD 
populations that include patients with AV grafts and CVC. 
Initially, we completed an analysis of all vascular access creations, which 
included both synthetic grafts and autogenous AV fistulae at our study site. The AV graft 
data was removed from the final analysis for several reasons, the most important of 
which was maintaining homogeneity of the study comparison.  In addition, only four 
synthetic grafts were included in the initial analysis, which greatly limited our ability to 
determine the full effect of synthetic grafts on access patency in this particular group of 
patients.  In the future, inclusion of additional study sites would expand our ability to 
draw conclusions from both AV graft and fistulae patients.  It is worth noting, however, 
that both datasets were quite similar.  Regardless of inclusion or exclusion of synthetic 
AV grafts from the study, both primary and secondary patency of upper arm access was 
significantly greater than that of forearm access.  Furthermore, cox regression analysis of 
the AV fistulae and AV graft population also did not show a relationship between patient 
comorbidities and access patency.  Again, we were able to note a trend towards upper 
arm as protective factor in maintaining access patency.  Patient survival was slightly 
decreased in the access population as a whole in comparison to the AV fistula population, 
potentially due to poorer overall survival of those patients who are not appropriate 
candidates for native fistulae (Appendix).   
          We suggest that in choosing a site for primary vascular access, the predicted long-
term survival of the patient be considered, choosing a more definitive solution for HD 
access in patients with an overall poor predicted survival.  In such poor risk patients, we 
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believe that preservation of proximal access becomes less important than establishing 
reliable, long-term access that will probably be durable for the remainder of the patient’s 
lifetime.  Although the standard algorithm for site selection starts with the wrist and 
forearm sites, our data suggests that the use of the larger upper arm veins are more likely 
to provide flow rates amenable to hemodialysis and are less likely to fail to mature, 
serving as a suitable initial access.  Preferential use of upper arm sites may thus avoid the 
need for temporary CVC usage, as well as reduce patient morbidity and redo surgery, 
improving patient satisfaction with care.   
 The results of this study are limited by its retrospective design, its small size, and 
its analysis of only a single center.  In particular, as a result of the studies retrospective 
nature, we could not control for surgical site, nor for the vein used in our population.  
Additionally, there are there are multiple vascular surgeons at the VA in West Haven, CT 
and we therefore could not control for surgical technique.   Also, while the computerized 
patient record system at the VA gave us excellent follow-up information on those patients 
dialyzed or followed by nephrology within the VA system, patient follow-up was 
somewhat limited for those patients dialyzed elsewhere to early postoperative time 
points.  As such, we chose to use the Gehan-Breslow statistic to compare our access 
patency curves in the current study.  Though the log-rank method of comparing stratified 
Kaplan-Meier plots is often used in vascular research, the Gehan-Breslow statistic 
emphasizes early data points on survival analyses, where our follow-up was most 
consistent, as opposed to the log-rank method which places more emphasis on late data 
points.   
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In young patients with few medical comorbidities and a reasonable predicted 
lifespan, we believe that, all other factors being equal, distal access remains a reasonable 
first choice option for permanent access.  Such patients will likely require the use of more 
proximal sites within their lifespan, as no fistula can yet provide infinite hemodialysis 
access. In this study, veterans requiring hemodialysis form a high risk population with 
poor survival and need for immediate access.  Additional studies are needed to define the 
impact of particular risk factors, especially in more heterogeneous ESRD populations.  
Nonetheless, commitment to maintaining hemodialysis access for this difficult group of 
patients may require abandoning the historical dogma of creating a distal hemodialysis 
access site first under all circumstances. 
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Appendix 
AV Fistula and Graft Analysis  
(Includes 4 AV grafts which are not included in the final analysis) 
Patient Demographics and Comorbidities 
A total of 122 patients underwent primary AV access creations, either native 
fistulae or synthetic grafts, at the VA Connecticut Healthcare System (West Haven 
Veterans Affairs Hospital) between April 2004 and December 2009.  A total of 46 
patients had upper arm fistula creations and 76 had forearm fistula creations.    
The demographics of the study population as a whole are listed in Table 1-1.  The 
mean age of patients who underwent upper arm access creations was 65.2 ± 1.8, and the 
mean age of patients who underwent forearm access creations was 65.6 ± 1.3; age did not 
vary significantly between the two groups (p= 0.868).  All of the patients were either 
Caucasian (66.4%) or African American (33.6%); patient race was similar across groups 
(p= 0.704).  The study population consisted of 120 males and 2 females.  
Hypertension was highly prevalent in both the upper (95.7%) and forearm access 
(100%) groups preoperatively.  Diabetes mellitus was also highly prevalent, and had a 
similar prevalence (p=0.44) across the two groups, present in 54.4% of the upper arm 
patients and 36.8% of the forearm patients.  There were a total of 37 patients (30.3%) 
who reported current tobacco use at the time of access creation; current tobacco use was 
more prevalent in the forearm group than the upper arm group (40.8% versus 13.0%, 
p=0.002).  Patients who had already initiated dialysis at the time of their operation were 
evenly distributed across the groups (43.5% upper versus 46.1% forearm, p=.929).  A 
total of 61 patients (50.0%) were identified as having heart disease; there was no 
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difference in prevalence across the upper and forearm groups (p=0.575). CAD and CHF 
were also similarly distributed across the study groups (p=0.998 for CAD; p=0.069 for 
CHF).   There was no significant difference between the two groups in the prevalence of 
pulmonary disease (P=0.13).  Prior stroke and TIA were identified in 13.1% and 10.9% 
of the upper arm patients and 10.9% and 0% of the forearm patients, respectively; this did 
not vary significantly across groups (p=0.768 for stroke and p=0.709 for TIA).  A total of 
twenty patients (16.4%) had a diagnosis of cancer at the time of operation, 10 of these 
patients were in the upper arm group, and 10 were in the forearm group (p=.323).  
 
Preoperative Labs, Measures, and Medications 
The mean preoperative albumin of the study population was 3.1 ± 0.1 and did not 
vary between the upper and forearm groups (P=0.179).  The mean creatinine was 5.2± .2; 
preoperative creatinine did not vary between study groups (p=0.31).  BMI and EF were 
similar in the upper and forearm groups (p=0.606 and p=0.744, respectively)  
At the preoperative visit 38.5% of patient were taking aspirin, 4.1% were taking 
an antiplatelet agent,  19.7% of patients were anticoagulated and 58.2% of patients were 
taking a statin medications did not vary significantly across groups.  
 
Surgical and Postoperative Variables 
A total of 4 AV grafts were included in the study.  The remaining 118 patients 
received native AV fistulas.  AV grafts were evenly distributed across the upper and 
forearm groups (p=.993).   The majority of patients received left upper extremity fistulas 
(85.3%, n=104); the distribution of surgical side did not vary significantly between 
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groups (p=0.367).   Preoperative duplex ultrasound vein mapping showed a significant 
difference between cephalic vein size at the wrist in the upper and forearm groups.  Those 
who received forearm fistulas had a mean cephalic vein width at the wrist of .317 ± .020 
cm versus .240 ± .0257 cm in those patients who ultimately received primary upper arm 
fistulas (p=.036).  Duplex ultrasound vein mapping of cephalic vein measurements at the 
distal humerus was similar between the two groups (p=.488).   A total of 53 patients were 
known to have successfully received hemodialysis via their primary AV fistula at least 
once to date in June of 2010; this did not vary across groups (p=0.879). 
 
Access Patency 
Kaplan-Meier survival analysis showed the median time to primary failure to be 
0.288 years in the forearm fistula group versus .940 years in the upper arm group.  Using 
the Gehan-Breslow statistic, the difference between the fistula survival curves (Figure 1-
1A) was significant (p=0.018).  When including secondary patency via additional 
invasive procedures for fistula repair, the Kaplan-Meier curves (Figure 1-1B) remained 
significantly different (p=0.04).  The median time to absolute fistula failure was 1.323 
years versus 3.491 years in the forearm and upper arm groups, respectively. 
Cox regression analysis of primary fistula patency (Table 2-1) in the study 
population as a whole showed no significant effect of patient comorbidities on fistula 
failure (p=0.685-0.988).  Preoperative labs, measures, and medications also did not 
significantly contribute to fistula failure (p=0.445-0.881).  There was a trend toward 
upper arm surgical site as a protective factor (hazard ratio=0.578, p=0.079).  Surgical side 
did not affect fistula patency (hazard ratio=0.915, p=0.814).  
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Patient Survival 
Kaplan-Meier survival (Figure 2-1) of the study population was shown to be 87% 
at 1.11 years, 64% at 3.14 years, and 47.8% at 5.011 years.  There were 36 patient deaths 
in the study group that occurred from the time of operation to June of 2010.  Cox 
regression analysis of long-term survival in the study population (Table 3) showed a 
trend toward diabetes mellitus as a risk factor for patient mortality (hazard ratio=0.74, 
p=0.075).  Antiplatelet therapy, as a proxy of underlying disease, also contributed to 
patient mortality (hazard ratio=1.465, P=0.018). Surgical site, upper versus forearm, did 
not influence patient mortality (hazard ratio=-0.0824, p=0.852).   
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Table 1-1.  Demographics and risk factors of AV Access Patients.  
Variable Total #  
Total 
(%) Upper  
Upper 
(%) Forearm  
Forearm 
(%) 
p- 
value 
Total Patients 
(n) 
122   46   76     
Age (yrs) 
65.4± 1.1  65.2 ± 1.8  65.6 ±  1.3  0.868 
Race 
        
Caucasian 
81 66.4% 32 69.6% 49 64.5% 0.704 
African 
American 
41 33.6% 14 30.4% 27 35.5%   
Gender 
        
Male 
120 98.4% 45 97.8% 75 98.7% 0.709 
Female 
2 1.6% 1 2.2% 1 1.3%   
Comorbidities 
              
Hypertension 
        
Yes 
120 98.4% 44 95.7% 76 100.0% 0.273 
No 
2 1.6% 2 4.4% 0 0.0%   
Diabetes 
Mellitus 
        
Yes 
73 59.8% 25 54.4% 48 63.2%   
No 
49 40.2% 21 45.7% 28 36.8% 0.44 
Current 
Smoker 
        
Yes 
37 30.3% 6 13.0% 31 40.8% 0.002 
No 
85 69.7% 40 87.0% 45 59.2%   
 
 
Current 
Dialysis 
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Yes 
55 45.1% 20 43.5% 35 46.1% 0.929 
No 
67 54.9% 26 56.5% 41 54.0%   
Heart Disease 
(CAD or CHF) 
        
Yes 
61 50.0% 21 45.7% 40 52.6% 0.575 
No 
61 50.0% 25 54.4% 36 47.4%   
CAD 
        
Yes 
57 46.7% 21 45.7% 36 47.4% 0.998 
No 
65 53.3% 25 54.4% 40 52.6%   
CHF 
        
Yes 
25 20.5% 5 10.9% 20 26.3% 0.069 
No 
97 79.5% 41 89.1% 56 73.7%   
Pulmonary 
Disease 
        
Yes 
32 26.2% 8 17.4% 24 31.6% 0.13 
No 
90 73.8% 38 82.6% 52 68.4%   
Stroke 
        
Yes 
16 13.1% 5 10.9% 11 14.5% 0.768 
No 
106 86.9% 41 89.1% 65 85.5%   
TIA 
        
Yes 
2 1.6% 0 0.0% 2 2.6% 0.709 
No 
120 98.4% 46 
100.0
% 74 97.4%   
Cancer 
        
Yes 
20 16.4% 10 21.7% 10 13.2% 0.323 
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No 
102 83.6% 36 78.3% 66 86.8%   
Preoperative 
Labs 
              
Albumin 
3.1  ± .1  3.0  ± .2  3.2  ± .1  0.179 
Creatinine 
5.2 ± .2  4.9 ± .3  5.4 ± .3  0.31 
Preoperative 
Measures 
              
BMI 
28.2  ± .8  27.5± 1.5  28.6 ± .9  0.606 
LVEF (%) 
49.9  ± 
2.4  
41.9  ± 
4.0  43.5  ± 3.0  0.744 
Medications 
              
ASA 
        
Yes 
47 38.5% 16 34.8% 31 40.8% 0.639 
No 
75 61.5% 30 65.2% 45 59.2%   
Anti-platelet 
        
Yes 
5 4.1% 1 2.2% 4 5.3% 0.717 
No 
117 95.9% 45 97.8% 72 94.7%   
Anticoagulated 
        
Yes 
24 19.7% 9 19.6% 15 19.7% 0.832 
No 
98 80.3% 37 80.4% 61 80.3%   
Statin 
        
Yes 
71 58.2% 24 52.2% 47 61.8% 0.39 
No 
51 41.8% 22 47.8% 29 38.2%   
Surgical 
Variables 
              
AVF or AVG 
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AVF 
118 96.7% 44 95.7% 74 97.4% 0.993 
AVG 
4 3.3% 2 4.4% 2 2.6%   
Side 
        
Right 
18 14.8% 9 19.6% 9 11.8% 0.367 
Left 
104 85.3% 37 80.4% 67 88.2%   
Duplex U/S 
Vein Mapping 
        
Cephalic @ 
Wrist (cm) 
.30 ± .02  .24 ± .03  .317 ± .02  0.036 
Cephalic @ 
Distal 
Humerus (cm)  
.39 ± .02  .37 ± .02  .4 ± .02  0.488 
Postoperative 
Variables 
              
AVF/AVG 
Used? 
        
Yes 
53 43.4% 21 45.7% 32 46.1% 0.879 
No 
63 51.6% 23 50.0% 40 54.0%   
Unknown 
6 4.9% 2 4.4% 4 5.3%   
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Table 2-1.  Cox Proportional Hazards Analysis of Factors Affecting Primary Access 
Patency 
Covariate Hazard Ratio 95%Conf-L 95%Conf-U p- value 
Age 1 0.975 1.027 0.921 
Comorbidities         
Hypertension 1.086 0.215 5.469 0.984 
Diabetes Mellitus 1.118 0.652 1.919 0.685 
Current Smoking 0.897 0.504 1.595 0.71 
Current Dialysis 0.897 0.48 1.675 0.733 
Heart disease (CHF or 
CAD) 1.074 0.587 1.962 0.818 
Pulmonary Disease 0.906 0.501 1.637 0.744 
Cancer 1.005 0.491 2.057 0.988 
Preoperative Labs         
Albumin 0.916 0.731 1.148 0.445 
Creatinine 0.956 0.83 1.101 0.528 
Preoperative 
Measures         
BMI 0.997 0.961 1.033 0.849 
LVEF (%) 0.998 0.988 1.009 0.751 
Medications         
ASA 0.901 0.515 1.577 0.715 
Antiplatelet 0.524 0.12 2.278 0.389 
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Anticoagulated 0.952 0.499 1.815 0.881 
Statin 1.204 0.667 2.173 0.537 
Surgical Variables         
Site-Upper arm 0.578 0.314 1.065 0.079 
Side 0.915 0.437 1.917 0.814 
 
 
Table 3-1. Cox Proportional Hazards Analysis of Factors Affecting AV Access Patient 
Survival. 
Covariate Hazard Ratio 95%Conf-L 95%Conf-U p-value 
Age 0.0294 -0.00917 0.0679 0.135 
Comorbidities         
Hypertension -17.016 -13787.583 13753.552 0.998 
Diabetes Mellitus 0.74 -0.0739 1.553 0.075 
Current Smoking -0.0593 -0.948 0.83 0.896 
Current Dialysis 0.32 -0.609 1.248 0.5 
Heart disease (CHF or 
CAD) -0.347 -1.274 0.581 0.464 
Pulmonary Disease 0.186 -0.719 1.092 0.687 
Cancer -0.0238 -1.073 1.026 0.965 
Preoperative Labs         
Albumin -0.118 -0.464 0.229 0.505 
Creatinine 0.0215 -0.158 0.201 0.814 
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Preoperative 
Measures         
BMI -0.00443 -0.0473 0.0385 0.84 
LVEF (%) 0.00733 -0.00736 0.022 0.328 
Medications         
ASA -0.304 -1.156 0.547 0.484 
Antiplatelet 1.465 0.249 2.682 0.018 
Anticoagulated -0.249 -1.181 0.683 0.6 
Statin 0.072 -0.793 0.937 0.871 
Surgical Variables         
Site-Upper arm -0.0824 -0.946 0.782 0.852 
Side -0.342 -1.418 0.734 0.533 
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Figure 1-1. Primary and secondary patency of forearm vs. upper arm access. (A) Kaplan-
Meier analysis of primary access patency.  (B) Kaplan-Meier analysis of secondary 
access patency. 
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Figure 2-1.  Kaplan-Meier analysis of post-operative survival (Native and synthetic 
fistulae). 
 
 
